(Q36423491)

14 August 2017

1 reference

title

Value of short-course antimicrobial therapy in community-acquired pneumonia (English)

1 reference

14 August 2017

0 references

Francesco Blasi

1

0 references

author name string

Paolo Tarsia

series ordinal

2

1 reference

14 August 2017

publication date

1 December 2005

1 reference

International Journal of Antimicrobial Agents

14 August 2017

published in

1 reference

14 August 2017

volume

26 Suppl 3

1 reference

14 August 2017

page(s)

S148-55

1 reference

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

ERS Task Force Report. Guidelines for management of adult community-acquired lower respiratory tract infections. European Respiratory Society

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Guidelines for severe community-acquired pneumonia in the western world

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Patient compliance with antibiotic treatment for respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Antibiotic noncompliance and waste in upper respiratory infections and acute diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Azithromycin versus comparative therapy for the treatment of community acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Effect of Macrolides as Part of Initial Empiric Therapy on Length of Stay in Patients Hospitalized With Community-Acquired Pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Severe pneumonia and a second antibiotic.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features, diagnosis, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Chlamydia pneumoniae community-acquired pneumonia: a review of 62 hospitalized adult patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Tissue-directed pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Single-dose azithromycin for acute otitis media: a pharmacokinetic/pharmacodynamic rationale

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Azithromycin Gonorrhea Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

Short course antibiotic therapy for respiratory infections: a review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980321-8

7 January 2021

10.1016/S0924-8579(05)80321-8

Identifiers

DOI

1 reference

14 August 2017

1 reference